Like eager buyers queuing for the latest iPhone, urban Indians are chasing next-generation weight-loss injections regardless of price. Eli Lilly’s Mounjaro has dethroned long-time bestseller Augmentin, sparking an unprecedented market boom for GLP-1 drugs.
Like eager buyers queuing for the latest iPhone, urban Indians are chasing next-generation weight-loss injections regardless of price. Eli Lilly’s Mounjaro has dethroned long-time bestseller Augmentin, sparking an unprecedented market boom for GLP-1 drugs.
<iframe src="https://hindustansphere.com/embed/cluster/df5f81c7dcca6e5d73f85837160dea43cd37b52f" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="The iPhone effect in healthcare: How Mounjaro is rewriting the economics of India’s pharma market"></iframe>
Like eager buyers queuing for the latest iPhone, urban Indians are chasing next-generation weight-loss injections regardless of price. Eli Lilly’s Mounjaro has dethroned long-time bestseller Augmentin, sparking an unprecedented market boom for GLP-1 drugs.
